We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+33.9%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$457M
AUM Growth
+$134M
Cap. Flow
+$78.2M
Cap. Flow %
17.13%
Top 10 Hldgs %
100%
Holding
9
New
1
Increased
1
Reduced
2
Closed
–

Top Buys

Rank Stock Value
1
AKUS
Akouos Inc
AKUS
+$103M
2
SCPH
scPharmaceuticals
SCPH
+$5.08M

Top Sells

Rank Stock Value
1
APRE icon
Aprea Therapeutics
APRE
+$21M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.52M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKUS
1
DELISTED
Akouos Inc
AKUS
$104M 22.69%
+4,605,784
New +$103M
APRE icon
2
Aprea Therapeutics
APRE
$7.4M
$85.8M 18.79%
110,633
-32,000
-22% -$21M
QTTB icon
3
Q32 Bio
QTTB
$450M
$84.1M 18.42%
307,551
– –
IDYA icon
4
IDEAYA Biosciences
IDYA
$3.41B
$49.2M 10.78%
3,463,066
– –
CABA icon
5
Cabaletta Bio
CABA
$439M
$40.9M 8.95%
3,669,263
– –
ARVN icon
6
Arvinas
ARVN
$520M
$33.5M 7.35%
1,000,000
– –
SCPH
7
DELISTED
scPharmaceuticals
SCPH
$28.2M 6.18%
3,831,474
+578,034
+18% +$5.08M
CRNX icon
8
Crinetics Pharmaceuticals
CRNX
$8.89B
$23.9M 5.23%
1,362,286
-500,000
-27% -$8.52M
CDTX
9
DELISTED
Cidara Therapeutics
CDTX
$7.4M 1.62%
100,326
– –

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q2 2020 Portfolio in Review

As of Q2 2020, 5AM Venture Management held 9 positions worth $457M, up 41% from $323M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

5AM Venture Management deployed $78.2M of net new capital in Q2 2020, opening 1 new position and adding to 1 existing holding. Its largest new stake was Akouos Inc: 4,605,784 shares worth $104M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Aprea Therapeutics, an estimated $21M trimmed.

  • 5AM Venture Management's largest Q2 2020 buy was Akouos Inc: 4,605,784 shares worth $104M.
  • 5AM Venture Management added most to scPharmaceuticals in Q2 2020, an estimated $5.08M increase.
  • 5AM Venture Management's biggest Q2 2020 reduction was Aprea Therapeutics, cutting an estimated $21M.
  • 5AM Venture Management's ten largest holdings make up 100% of its $457M portfolio in Q2 2020.
  • 5AM Venture Management opened 1 new position and closed 0 in Q2 2020.
  • 5AM Venture Management's portfolio value rose 41% quarter-over-quarter to $457M.

Based on 5AM Venture Management's 13F filing for Q2 2020, filed 5 Aug 2020.